Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report
- PMID: 20730485
- DOI: 10.1007/s10549-010-1125-3
Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report
Abstract
Hereditary breast cancer syndrome was firstly associated with BRCA1 and BRCA2 genes the mutations of which confer high risk to develop breast and/or ovarian cancer. Double heterozygosity is a rare condition in which both BRCA1 and BRCA2 mutations are present in a family at the same time. In the current study, a family with double heterozygosity has been reported. Furthermore, for the first time a molecular analysis in both proband lineages, maternal and paternal, has been reported to understand the provenience of both germinal mutations.The case regards a woman who developed breast and ovarian cancer with liver metastasis which presented two mutations, each in the two genes, transmitted from her mother and her father, respectively. In this family all available members have been investigated. The concomitant presence of these peculiar mutations was never reported before suggesting a link with Caucasian population from Southern Italy.
Similar articles
-
Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.Breast Cancer Res Treat. 2010 Nov;124(1):251-8. doi: 10.1007/s10549-010-0853-8. Epub 2010 Apr 7. Breast Cancer Res Treat. 2010. PMID: 20373018
-
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.Clin Cancer Res. 2002 Dec;8(12):3776-81. Clin Cancer Res. 2002. PMID: 12473589
-
Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.Hum Mutat. 2002 Sep;20(3):230. doi: 10.1002/humu.9049. Hum Mutat. 2002. PMID: 12203997
-
Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87. doi: 10.1006/gyno.2000.5861. Gynecol Oncol. 2000. PMID: 10985881 Review.
-
Prevention and Screening in Hereditary Breast and Ovarian Cancer.Oncology (Williston Park). 2016 Oct 15;30(10):896-904. Oncology (Williston Park). 2016. PMID: 27753056 Review.
Cited by
-
Case Report: Clinical impact of BRCA1 and BRIP1 vs. BRCA1 and BRCA2 germline double heterozygosity in ovarian cancer: a comparative case study.Front Oncol. 2025 Jul 24;15:1614373. doi: 10.3389/fonc.2025.1614373. eCollection 2025. Front Oncol. 2025. PMID: 40777133 Free PMC article.
-
Double Heterozygosity for Germline Mutations in Chinese Breast Cancer Patients.Cancers (Basel). 2024 Jul 15;16(14):2547. doi: 10.3390/cancers16142547. Cancers (Basel). 2024. PMID: 39061189 Free PMC article.
-
Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?Int J Mol Sci. 2022 Sep 29;23(19):11499. doi: 10.3390/ijms231911499. Int J Mol Sci. 2022. PMID: 36232793 Free PMC article.
-
BRCA1 and BRCA2 Testing through Next Generation Sequencing in a Small Cohort of Italian Breast/Ovarian Cancer Patients: Novel Pathogenic and Unknown Clinical Significance Variants.Int J Mol Sci. 2019 Jul 12;20(14):3442. doi: 10.3390/ijms20143442. Int J Mol Sci. 2019. PMID: 31336956 Free PMC article.
-
Five Italian Families with Two Mutations in BRCA Genes.Genes (Basel). 2020 Dec 3;11(12):1451. doi: 10.3390/genes11121451. Genes (Basel). 2020. PMID: 33287145 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous